Michael Lutz

2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark.

Noscendo GmbH is a diagnostics company, which engages in the identification and assessment of bloodstream-associated pathogens and other infections. It offers logistics, sample preparation, sequencing, data analysis, and reports. The company was founded by Philip Stevens, Silke Grumaz and Kai Sohn and is headquartered in Duisburg, Germany.

NTP Nano Tech Projects SRL develops Nano-Eye, an advanced optical-laser microscopy device that can achieve optical resolutions below the micron size. The company was founded by Adolfo Carloni, Gianluca Maroncelli and Massimo Galavotti in 2012 and is headquartered in Sant'Angelo in Vado, Italy.

Iota Sciences Ltd. develops fluid-shaping technology for life sciences and biomedicine, offering innovative solutions for ambitious research. The company was founded by Peter Cook, Edmond Walsh and Alexander Feuerborn in 2016 and is headquartered in Oxford, the United Kingdom.

HepaRegeniX GmbH engages in the development of treatment for acute and chronic liver diseases. It focuses on Mitogen-Activated Protein Kinase 4, which unlocks the regenerative capacity of hepatocytes even in severely diseased livers. The company was founded in by Wolfgang Albrecht in 2017 and is headquartered in Tuebingen, Germany.

Lophius Biosciences GmbH develops and markets T-cell-based diagnostic test systems. The firm specializes in the development of products for the diagnosis and immuno monitoring of virus-specific immune responses. It also provides customized services in the field of cell-based bioactivity, as well as quality tests for pharmaceutical active substances. The firm focuses on improving therapy control and personalized treatment of patients in the area of transplantation medicine and infectious and autoimmune diseases. The company was founded by Ludwig Deml and Fritz Schwarzmann in 2002 and it is headquartered in Regensburg, Germany.